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Abstract 
Duchenne Muscular Dystrophy (DMD) is an X chromosome-linked disease characterized by 
progressive physical disability, immobility and premature death in affected boys. Underlying the 
devastating symptoms of DMD is the loss of dystrophin, a structural protein which connects the 
extracellular matrix to the cell cytoskeleton and provides protection against contraction-induced 
damage in muscle cells, leading to chronic peripheral inflammation. However, dystrophin is also 
expressed in neurons within specific brain regions, including the hippocampus, a structure associated 
with learning and memory formation. Linked to this, a subset of boys with DMD exhibit non-
progressing cognitive dysfunction, with deficits in verbal, short-term and working memory. 
Furthermore, in the genetically comparable dystrophin-deficient mdx mouse model of DMD, some, 
but not all, types of learning and memory are deficient and specific deficits in synaptogenesis and 
channel clustering at synapses has been noted. Little consideration has been devoted to the cognitive 
deficits associated with DMD in comparison to the research conducted into the peripheral effects of 
dystrophin deficiency. Therefore, this review will focus upon what is known about the role of full 
length dystrophin (Dp427) in hippocampal neurons. The importance of dystrophin in learning and 
memory will be assessed and the potential importance that inflammatory mediators, which are 
chronically elevated in dystrophinopathies, may have on hippocampal function will also be evaluated.  
 
Key Words (5 max): Duchenne Muscular Dystrophy, dystrophin, hippocampus, learning, 
memory. 
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Introduction 
The fatal, X chromosome-linked disease, Duchenne muscular dystrophy (DMD) is caused by 
the loss of the structural protein, dystrophin (Bulfield et al. 1984). Interactions between 
dystrophin and the dystrophin associated protein complex (DAPC), which includes the 
membrane spanning β dystroglycan component, serves to link the sub-sarcolemmal 
cytoskeletal actin to the extracellular matrix in skeletal muscle. In such contracting cells 
dystrophin, through interactions with the DAPC, protects the sarcolemma against the 
mechanical stresses of repeated contractions. Thus, loss of functional dystrophin, which 
comprises 0.1% of the total human genome (Barbujani et al. 1990; Koenig et al. 1987), 
causes muscle fibres to become more susceptible to contraction-induced damage. This, in 
turn, results in  muscle inflammation and myophagocytosis (Anderson et al. 1987) leading to 
progressive physical disability, eventual immobility and, finally, premature death in affected 
boys. There is currently no cure for DMD, with patients experiencing an average life 
expectancy of just over 20 years (Yiu & Kornberg 2008), and most eventually succumbing to 
death via cardio-respiratory failure. 
 
Chronic inflammation is a key symptom and contributory factor in the pathogenesis of DMD, 
due in part to the secretion of pro-inflammatory immune mediators from damaged 
dystrophin-deficient muscle fibers (De Paepe and De Bleecker 2013; Porter et al. 2002). Pro-
inflammatory cytokines, including Tumor necrosis factor (TNF)α (Kuru et al. 2003; Porreca 
et al. 1999), interleukin (IL)-1β (Evans et al. 2009), IL-6 (Messina et al. 2011; Rufo et al. 
2011) and the promotor of ongoing inflammation, IL-17 (De Pasquale et al. 2012) are 
elevated in muscle biopsies from DMD patients.  
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Although dystrophinopathies have principally been studied in the context of skeletal muscle 
dysfunction, DMD itself is actually a multi-system disorder due to the fact that dystrophin is 
also expressed in cardiac and smooth muscle, endocrine glands and neurons. In healthy 
individuals, neurons in the central nervous system (CNS) express full length dystrophin 
(Dp427). Specifically, it is expressed in the hippocampus, cerebellum, cerebral cortex and 
amygdala (Bies et al. 1992; Knuesel et al. 2000; Lidov et al. 1993; Lidov et al. 1990; 
Sekiguchi et al. 2009). Consistent with the functional importance of dystrophin in the CNS, 
boys with DMD often exhibit varying degrees of non-progressing cognitive impairment 
(Anderson et al. 2002; Bresolin et al. 1994), with their intelligence quotients (IQ) shifted 
downward one standard deviation below the normal range (Felisari et al. 2000; Nardes et al. 
2012). Moreover, boys with DMD have difficulty communicating. They exhibit social 
behavior problems and have poor facial affect recognition (Hinton et al. 2007; Hinton et al. 
2006). Interestingly, expression of Dp71, a protein product produced through a mutation in 
the dystrophin gene and only expressed in the CNS, has been linked to intellectual disability 
without an attendant muscular dystrophy phenotype (de Brouwer et al. 2014). In the context 
of the frontal cortex and hippocampus, both of which facilitate learning and memory 
processes, DMD patients exhibit deficits in verbal, short-term and working memory (Hinton 
et al. 2000; 2001; Snow et al. 2013). As it is now recognized that activation of the immune 
system in the periphery greatly influences the normal function of the central nervous system 
(Marin and Kipnis 2013), this review will assess the possible role of inflammatory mediators 
in DMD-associated cognitive dysfunction focusing on the hippocampus. 
 
The potential role of inflammatory molecules in DMD-associated cognitive dysfunction. 
Chronic inflammation is a key aspect of DMD pathophysiology. Indeed, corticosteroids with 
potent anti-inflammatory effects are the most effective treatment for delaying the onset and 
5 
 
progression of the disease (Gloss et al. 2016). Skeletal muscle biopsies exhibit necrotic and 
degenerating fibers surrounded by macrophages and CD4+ lymphocytes in the early stages of 
the disease, when new myocytes are still being produced, however, the capacity to regenerate 
new myofibres becomes exhausted and muscle fibers are eventually replaced by connective 
and adipose tissue. There is also evidence of immune cell infiltration  into muscle tissue and 
activation of the complement system (Haslett et al. 2002), which is an important effector arm 
of both the innate and adaptive divisions of the immune system. The inflammatory response 
is due, in part, to the secretion of cytokines from damaged dystrophin-deficient muscle fibers 
(De Paepe and De Bleecker 2013; Porter et al. 2002). Consistent with this, DMD muscle 
biopsies display altered cytokine profiles with elevated levels of pro-inflammatory mediators 
such as TNFα (Kuru et al. 2003; Porreca et al. 1999), IL-1β (Evans et al. 2009), IL-6 
(Messina et al. 2011; Rufo et al. 2011) and IL-17 (De Pasquale et al. 2012).  
 
Whilst cytokines have a well characterized role in the response of tissues to infection, these 
signaling molecules also have neuromodulatory actions. In addition to immune cells, neurons, 
glia and the endothelial cells of the microvasculature in the CNS secrete cytokines and also 
express receptors for these immune mediators. There is significant crosstalk between the 
immune and nervous systems, as cytokines can have indirect effects on neuronal activity by 
stimulating secretion of neuromodulatory molecules from glia or endothelial cells (Allan and 
Rothwell 2001; Montgomery and Bowers 2012). Moreover, they can bind directly to 
receptors on neurons, where their neuromodulatory actions can subsequently influence 
cognitive function. The hippocampus, a structure upon which the acquisition of new 
declarative memories is absolutely dependent, expresses receptors for IL-1β (Gardoni et al. 
2011), TNFα (Sairanen et al. 2001), and IL-6 (Schobitz et al. 1993).  
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Cytokines can promote neurite outgrowth, neurogenesis and neuronal survival, in addition to 
being able to regulate synaptic transmission and synaptic plasticity (Marin and Kipnis 2013). 
However, chronically elevated levels of inflammatory cytokines can result in neuronal 
dysfunction. For example, IL-1 (Terrando et al. 2010) and IL-6 (Sparkman et al. 2006) have 
been implicated in lipopolysaccharide (LPS) -evoked cognitive dysfunction and TNF receptor 
1 facilitates memory deficits associated with sepsis (Calsavara et al. 2015; Haslett et al. 
2002). IL-17 is also a central regulator of CNS inflammatory responses and works 
synergistically with TNF and IL-1 under inflammatory conditions (Gaffen 2009). It is 
upregulated in hippocampal neurons following stimulation with LPS, indicating a role for it 
in neuroinflammation and the associated cognitive impairment (Sun et al. 2015). Disease 
states associated with such pathophysiology include epilepsy, stress-related disorders and 
neurodegenerative diseases (Allan et al. 2005; Glass et al. 2010; Griffin 2006; Nguyen et al. 
1998; Vezzani et al. 2011). As neuro-immune interactions promote homeostasis of the 
nervous system (Marin and Kipnis 2013), chronic inflammation may also be a contributory 
factor in cognitive dysfunction exhibited by dystrophin-deficient DMD patients. 
 
Expression of dystrophin in the CNS. 
The dystrophin gene has many independent, and tissue-specific, promoters for brain and 
skeletal muscle cells (Blake et al. 2002). Within the brain, dystrophin expression is only one 
tenth of that found in muscle. However, brain tissue exhibits much greater variability in the 
protein products that are generated from the dystrophin gene. Included are the full length 
protein (Dp427), which this review will focus on, and shorter proteins (Dp71, Dp260, Dp140 
and Dp116) (Gorecki and Barnard 1995). Quantitatively, Dp71 is the main dystrophin gene 
product in the brain and its location, around perivascular astrocyte endfeet (Haenggi et al. 
2004; Tadayoni et al. 2012), suggest a role in blood brain barrier (BBB) function (Amiry-
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Moghaddam et al. 2004), which may be a consideration in the ability of peripheral 
inflammatory molecules gaining access to the brain.  
 
In the CNS, Dp427 is only found in neurons, and only within specific regions of the brain 
such as the hippocampus, amygdala, cerebellar Purkinje cells and neocortex (Anderson et al. 
2002; Bies et al. 1992; Chamberlain et al. 1988; Chelly et al. 1990; Comim et al. 2011; 
Cyrulnik and Hinton 2008; Knuesel et al. 2000; Lidov 1996; Sekiguchi et al. 2009). Similar 
to its function in striated muscle, dystrophin in neurons and glia associates with the DAPC of 
membrane-spanning proteins that link the intracellular cytoskeleton to the extracellular 
matrix. However, the DAPC in the brain is unlikely to act as a mechanotransducer as it does 
in skeletal muscle (Hendriksen et al. 2015). Further, several variants of brain DAPC exist due 
to both the variety of CNS dystrophin protein products and the fact that they can also 
associate with DAPC components which are absent from skeletal muscle cells, such as β-
dystrobrevin, ε-sarcoglycan, and the γ-syntrophins (Waite et al. 2012; Waite et al. 2009). It is 
likely however, that this interaction of Dp427 with the DAPC in neurons does play a critical 
role in the formation and maintenance of new synaptic connections (Rodius et al. 1997).  
 
Changes in the structure and function of dystrophic brains 
DMD patients 
Considerable debate continues as to whether loss of Dp427 alters the architecture of DMD 
brains, with some investigators noting relatively minor changes in DMD brains (al-Qudah et 
al. 1990; Bresolin et al. 1994; Dubowitz and Crome 1969; Rae et al. 1998) and others 
reporting a range of brain abnormalities including neuronal loss, neurofibrillary tangles, 
dendritic changes and cortical atrophy (Itoh et al. 1999; Jagadha and Becker 1988; Lv et al. 
2011; Rosman 1970; Rosman and Kakulas 1966; Septien et al. 1991; Yoshioka et al. 1980). 
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Indeed, no clear correlations have been made between the different types of brain 
abnormalities observed in DMD patients and the degree of intellectual impairment suffered. 
Moreover, investigations into possible biochemical and neuromodulatory mechanisms 
underlying the dystrophin-associated cognitive deficits in human DMD are relatively limited. 
The brains of DMD boys have been reported to be hypometabolic in their use of glucose 
(Bresolin et al. 1994; Lee et al. 2002), a phenomenon which occurs in other conditions with 
known associated cognitive deficits, and may be related to reduced synaptic activity (Jueptner 
and Weiller 1995).  
 
Mdx mice 
The functional role of specific proteins within the CNS is usually made much easier with the 
development of transgenic knockin or knockout mouse models. Therefore, the fortuitous 
generation of the mdx mouse (Bulfield et al. 1984), which is deficient in Dp427 (Blake and 
Kroger 2000) due to a nonsense mutation occurring in exon 23 of the dystrophin gene 
(Arechavala-Gomeza et al. 2010), provided an opportunity for more functional studies on 
DMD to be carried out. Mdx mice are genetically comparable to human DMD and 
recapitulate striated muscle dysfunction, where skeletal muscle fibres progress through cycles 
of degeneration and regeneration until functional myofibres are replaced by collagen and 
adipocytes. Degeneration and regeneration of myofibres is associated with muscle 
inflammation (Grounds et al. 2008), but fibrosis and loss of limb muscle function is not as 
severe in mdx mice as in humans (Dangain & Vrbova 1984; Coulton et al. 1988), possibly 
due to compensatory mechanisms (Manning and O'Malley 2015). Nonetheless, consistent 
with human studies (al-Qudah et al. 1990; Bresolin et al. 1994; Dubowitz and Crome 1969; 
Rae et al. 1998), most studies in mdx mice failed to note any gross abnormalities in brain 
structure (Bulfield et al. 1984; Miranda et al. 2009; Torres and Duchen 1987; Yoshihara et al. 
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2003). However, changes in cell number, size and/or shape were noted in regions of the 
cerebral cortex and brainstem of mdx mice (Carretta et al. 2004; Carretta et al. 2001; Carretta 
et al. 2003; Minciacchi et al. 2010; Sbriccoli et al. 1995) and enlargement of the lateral 
ventricles, possibly due to grey matter atrophy has also been reported (Xu et al. 2015).  
Similar to findings in DMD patients, muscle levels of IL-6, TNFα and IL-1β are elevated in 
mdx mice (Huang et al. 2009; Huynh et al. 2013; Kurek et al. 1996), however changes in 
circulating or CNS levels of inflammatory mediators in this mouse model has not yet been 
reported.  
 
Hippocampal dysfunction in mdx mice 
The neurobehavioral profile of mdx mice is characterised by deficits in cognitive function 
(Chaussenot et al. 2015; Muntoni et al. 1991; Perronnet et al. 2012; Vaillend et al. 2004; 
Vaillend et al. 1995), behaviors which are linked to dysregulation of hippocampal and 
amygdalar function. For example, the mdx mouse exhibits deficits in its capacity to learn and 
store spatial memories relative to controls (Vaillend et al. 2004; Vaillend et al. 1995) and it 
also displays deficiencies in associative learning as well as in general processes of memory 
consolidation which are dependent upon both the hippocampus and the amygdala 
(Chaussenot et al. 2015). Changes in long- and short-term memory formation and 
consolidation have been associated with altered synapse morphology and plasticity linked to 
a loss of Dp427 (Miranda et al. 2009; Vaillend et al. 2004; Vaillend et al. 1995). 
Interestingly, other in vivo and in vitro hippocampal-dependent functions, such as spatial 
learning, CA1 NMDA-dependent long term potentiation (LTP), and its converse, long term 
depression (LTD), have either been found to be intact (Sesay et al. 1996) or actually 
enhanced relative to controls (Dallerac et al. 2011; Vaillend and Billard 2002; Vaillend et al. 
1998; Vaillend et al. 2004; Vaillend et al. 1999).  
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Dysregulated synaptic receptor clustering in the mdx mouse 
GABAA receptors 
Within the hippocampus, alterations in the number and localisation of several receptor types 
having been noted in the absence of Dp427. Dp427 is exclusively expressed post-synaptically 
in dense puncta on neuronal cell membranes of hippocampal inhibitory synapses (Brunig et 
al. 2002; Kim et al. 1992; Knuesel et al. 2000; Knuesel et al. 1999; Levi et al. 2002; 
Sakamoto et al. 2008). Here, through its interaction with components of the DAPC, it makes 
a crucial contribution to synapse structure and function (for reviews see Haenggi and Fritschy 
2006; Hendriksen et al. 2015; Perronnet and Vaillend 2010; Waite et al. 2012). This is likely 
to be facilitated through interactions between the syntrophin-dystrobrevin sub complex 
(Compton et al. 2005; Matsumura et al. 1992), β-dystroglycan and the synaptic cell-adhesion 
molecules, neurexin and neuroligin (Craig and Kang 2007; Graf et al. 2004; Kang et al. 2008; 
Sudhof 2008; Sugita et al. 2001; Waite et al. 2012; Zhang et al. 2010), all of which may be 
critically involved in anchoring GABAergic (for review see Fritschy et al. 2012), and other 
neurotransmitter receptors or channels, in place at specific points in the post-synaptic 
membrane (Krasowska et al. 2014). Thus, loss of dystrophin leads to the generation of 
malformed synapses (Knuesel et al. 1999; Knuesel et al. 2001; Kueh et al. 2008; Miranda et 
al. 2011; Miranda et al. 2009), which will significantly alter how affected neurons respond to 
afferent stimuli (Graciotti et al. 2008). This will inevitably disrupt the precise and 
coordinated spatiotemporal and stratified neural network activity that is critical for normal 
hippocampal function and cognition (for review see Cohen et al. 2015). 
 
This feature of dystrophin function has been particularly well described for inhibitory 2 
subunit-containing GABAA receptors in CA1 and CA3 regions of the hippocampus (Knuesel 
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et al. 1999; Knuesel et al. 2001). Indeed, the fact that GABAA receptor clustering in dendritic 
and pyramidal layers of mdx mice can be restored to normal levels by administering specific 
antisense oligonucleotides, established for the first time a direct link between receptor 
clustering and Dp427 expression (Vaillend et al. 2010). Furthermore, the proposed cellular 
correlate of new memory formation, NMDA-dependent LTP, can be restored in mdx mice 
using the same treatment. This evidence supports the suggestion that clustering of 
GABAergic neurotransmitter receptors at inhibitory synapses is essential for normal neuronal 
excitability and synaptic transmission (Dallerac et al. 2011).  
 
More recently, the Wnt intracellular signalling pathway has emerged as an important player in 
the development and maintenance of normal neuronal structures within the CNS as well as in 
modulating synaptic plasticity and cognitive function (for reviews see Inestrosa and Arenas 
2010; Oliva et al. 2013). Significantly, Fuenzalida et al. (2016) demonstrated that the 
aforementioned deficiency in GABAergic signalling within hippocampal CA1 neurons of 
mdx mice can be restored by stimulating the non-canonical Wnt-5a pathway, which serves to 
increase the number of inhibitory synapses and GABAA receptors in CA1 without any 
attendant increase in GABA release probability or release sites.  
 
Nicotinic acetylcholine receptors (nAChRs) 
Alterations in the expression, distribution and function of other receptor subtypes have also 
been noted in dystrophic brains. For example, behavioral studies reporting a reduced response 
to nicotine in a passive avoidance memory task, suggested altered nAChR expression or 
responsivity (Coccurello et al. 2002), work that has been supported by in vitro research 
demonstrating a reduction of hippocampal 3 nAChR mRNA (Wallis et al. 2004) and 7 
nAChR binding sites (Ghedini et al. 2012). However, these alterations, which would be 
expected to lead to decreased nicotinic cholinergic synaptic signalling, appear to be 
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compensated for by an upregulation in nAChR-mediated cholinergic transmission in the same 
brain region (Parames et al. 2014). However, the fact that the expression of hippocampal 
muscarinic receptors is unchanged in dystrophic mice (Yoshihara et al. 2003) indicates that 
dystrophin does not exert a generalised effect on the expression of all cholinergic receptor 
subtypes. Nonetheless, a reduction in acetylcholinesterase activity in the hippocampus of mdx 
mice may be illustrative of a non-receptor dependent form of compensation for an overall 
reduction in cholinergic signalling in the CNS of dystrophic mice (Cohen et al. 2015; Comim 
et al. 2011). 
 
Kainic acid (KA)/AMPA receptors 
Yoshihara et al (2003) demonstrated that KA/AMPA receptor density was significantly 
reduced in several brain regions, including the hippocampus, in the mdx mice relative to WT 
animals. However this may reflect another homeostatic compensatory mechanism, this time 
for increased glutamatergic input (Miranda et al. 2011; Miranda et al. 2009).  
 
In the context of this review it is interesting to note that changes in neuromodulatory 
cytokines such as IL-6, IL-1β and TNFα are known to effect both pre-synaptic and post-
synaptic channels and receptors (Vezzani and Viviani 2015). Indeed, as previously 
mentioned, circulating levels of these proinflammatory cytokines are elevated in DMD 
patients (Chahbouni et al. 2010) but, as yet there is no evidence that brain levels of these 
neuromodulatory cytokines are altered. 
 
Changes in hippocampal synaptic function in mdx mice 
Consistent with reduction in the size and number, but not function (Kueh et al., 2008), of 
post-synaptically-localised neuronal GABAA receptor clusters in mdx mice (Anderson et al. 
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2002; Knuesel et al. 1999; Knuesel et al. 2001; Kueh et al. 2011; Kueh et al. 2008; Vaillend 
et al. 2010), one might expect reduced inhibitory input to the neuron to be manifested as a 
measurable increase in overall neuronal excitability in affected regions of the brain. However, 
the picture emerging from electrophysiological studies is not quite so straightforward.  
Whilst NMDA-induced Schaffer collateral - CA1 LTP in mdx hippocampus is abnormally 
enhanced in a bicuculline-sensitive manner which would tally with reduced inhibitory input 
onto the CA1 neurons (but see Sesay et al. 1996; Vaillend et al. 1998; Vaillend et al. 2004; 
Vaillend et al. 1999), a significant increase in the frequency of spontaneous miniature 
inhibitory post-synaptic currents (mIPSCs) has been recorded from mdx CA1 hippocampal 
neurons. This is likely due to increased neurotransmitter release probability from somatic 
inhibitory synapses contacting CA1 pyramidal neurons (Graciotti et al. 2008), due to an 
increased number of inhibitory synapses innervating the mdx CA1 neurons (Miranda et al. 
2009; Perronnet and Vaillend 2010). This suggestion was supported by a contemporaneous 
study by Del Tongo et al. (2009) in which a significant increase in the number of 
parvalbumin-expressing GABAergic interneurons in the dorsal hippocampus of the mdx 
mouse was observed.  
 
The increase in hippocampal GABAergic innervation associated with absence of dystrophin 
may have arisen as a systemic compensation for impaired GABAergic synaptic clustering and 
function but still appears to be insufficient to fully restore GABA concentrations within the 
hippocampus (Xu et al. 2015). Graciotti et al. (2008) speculated that an increase in inhibitory 
transmitter release specifically onto CA1 neurons may also occur via a retrograde signalling 
system, possibly involving pre-synaptically expressed scaffolding proteins such as neurexins 
(Craig and Kang 2007; Kang et al. 2008; Pilgram et al. 2010; Sudhof 2008; Sugita et al. 
2001; Zhang et al. 2010). Not only do neurexins form direct structural links with the DAPC, 
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which, in turn, facilitates the post-synaptic clustering of GABAA receptors (Fritschy et al. 
2012; Graf et al. 2004; Krasowska et al. 2014; Kueh et al. 2008), but they also modulate pre-
synaptic release of neurotransmitters and vesicle cycling (Futai et al. 2007; Olsen et al. 2006; 
Sugita et al. 2001; Tanaka et al. 2000). Evidence for such a retrograde signalling mechanism 
has emerged from studies on Drosophila, where dystrophin isoforms retrogradely regulate 
pre-synaptic transmitter release from both inhibitory as well as excitatory synapses 
(Bogdanik et al. 2008; Fradkin et al. 2008; van der Plas et al. 2006; Wairkar et al. 2008). 
However, conclusive evidence for the existence of such a retrograde signalling mechanism 
occurring specifically at mammalian inhibitory synapses, where Dp427 is exclusively 
expressed, remains elusive. Tantalisingly, Vaillend and colleagues have demonstrated that 
dystrophin loss affects pre-synaptic ultrastructural organisation in hippocampal excitatory 
glutamatergic synapses, by increasing not only the size of their PSDs (Miranda et al. 2009) 
but also the density of docked vesicles (Miranda et al. 2011). Such a change in the density of 
docked vesicles, possibly in conjunction with reduced dendritic inhibition (Vaillend and 
Billard 2002; Vaillend et al. 1999), is likely to alter excitatory synapse physiology and may 
account for the facilitated induction of NMDA-dependent LTP observed at Schaffer 
collateral-CA1 synapses in mdx mice (Vaillend and Billard 2002). Moreover, such a 
potentiation of excitatory output could, at least partially, account for the increase in mIPSC 
frequency observed in CA1 of mdx mice (Graciotti et al. 2008) as it is well established that 
hippocampal inhibitory interneurons are directly innervated by glutamatergic excitatory 
projections emanating from the pyramidal cell layer (Gulyas et al. 1993; McBain and 
Dingledine 1993). It is as yet unclear how a cytoskeletal protein expressed exclusively at 
inhibitory CA1 synapses can exert such an effect on excitatory synapses, but dysregulation of 
calcium homeostasis (Hopf and Steinhardt 1992; Tuckett et al. 2015), defective brain 
vascular permeability (Goodnough et al. 2014; Nico et al. 2004) and/or dysbindin 
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relocalization (Miranda et al. 2011) have been posited as possible mechanisms for this 
phenomenon.  
 
A role for immune molecules in synaptic transmission 
Although not yet investigated in dystrophin-deficient models, it is interesting to note that 
receptors for immune molecules in the CNS have expression patterns that bear similarities to 
the synaptic receptors discussed previously. The major histocompatibility complex class I 
(MHCI) is a complex molecule which provides the cellular signature that allows the immune 
system to differentiate between self and non-self. MHCI is expressed in neurons (Corriveau 
et al. 1998) of the thalamus, hippocampus, cortex and cerebellum (Marin and Kipnis 2013), 
the latter three showing overlap with brain regions expressing DP427 (Anderson et al. 2002; 
Bies et al. 1992; Chamberlain et al. 1988; Chelly et al. 1990; Comim et al. 2011; Cyrulnik 
and Hinton 2008; Knuesel et al. 2000; Lidov 1996; Sekiguchi et al. 2009). MHCI is 
upregulated in skeletal muscle from muscular dystrophy patients (Nagappa et al. 2013) but it 
is not yet known if there are changes in expression of this immune molecule in the CNS of 
DMD patients. However, MHCI has been detected clustered at the post-synaptic density of 
synapses of hippocampal neurons, (Goddard et al. 2007), the site of expression of post-
synaptic receptors which are altered in dystrophic hippocampal neurons. Furthermore, 
hippocampal neurons from a MHCI knockout mouse display enhanced synaptic plasticity and 
potentiated LTP (Goddard et al. 2007; Huh et al. 2000), features which bear a striking 
similarity to those reported in mdx mice (Dallerac et al. 2011; Vaillend and Billard 2002; 
Vaillend et al. 1998; Vaillend et al. 2004; Vaillend et al. 1999).  
 
Cytokines represent another class of immune molecules which are crucial to the homeostatic 
function of the nervous system and, given the chronic elevations in their secretion in 
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dystrophinopathies, they are discussed below in relation to their potential role in the changes 
in hippocampal structure and function in dystrophic neurons.  
 
Role of cytokines in hippocampal function 
IL-1β 
IL-1β is crucial for the generation of NMDA-dependent LTP in hippocampal CA1 neurons 
(Schneider et al. 1998), and reduced signalling through the IL-1 receptors results in impaired 
learning (Goshen et al. 2007). However, overexpression, or elevated levels of IL-1β also 
results in memory deficits (Moore et al. 2009) and decreased synaptic strength (Ross et al. 
2003). In terms of its effects on post-synaptic receptors, IL-1β can increase the surface 
expression of hippocampal GABAA receptors and potentiate GABA-evoked inhibitory 
currents (Wang et al. 2012), features that have been observed in mdx hippocampal neurons 
(Graciotti et al. 2008). A relationship between IL-1β and cholinergic signalling in the 
hippocampus has also been postulated as IL-1β caused a reduction in extracellular 
acetylcholine in this brain region (Rada et al. 1991) an effect that was also correlated with 
memory defects (Taepavarapruk and Song 2010). This could perhaps be compared to the 
reduced sensitivity of the mdx hippocampus to cholinergic agonists (Coccurello et al. 2002) 
due to decreased nAChR binding sites (Ghedini et al. 2012)  
 
IL-6 
Local increases in hippocampal IL-6 are observed following intense synaptic or neuronal 
activity such as that induced by LTP protocols (Balschun et al. 2004; Jankowsky et al. 2000). 
However, in contrast to the effects of IL-1β, Balschun et al. found that inhibition of IL-6-
mediated signalling in ‘healthy’ brains actually improved long-term memory, suggesting a 
possible negative regulatory role for IL-6 on LTP by limiting memory acquisition (Balschun 
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et al. 2004; Li et al. 1997). These findings correlate with in vivo behavioral studies which 
have demonstrated that neutralisation of IL-6 improved long term spatial memory in rats 
(Balschun et al. 2004), and that IL-6 knockout mice displayed an enhanced capacity for 
learning and memory (Braida et al. 2004). However, conversely, another study found that 
hippocampus-dependent learning was impaired in IL-6 knockout mice (Baier et al. 2009). 
Over-expression of IL-6 results in alterations in both inhibitory and excitatory synapses, and 
abnormal dendritic spine formation. These structural alterations are associated with 
impairments in cognitive abilities and deficits in learning, similar to symptoms exhibited by 
individuals with autism (Wei et al. 2012). This is an interesting finding as a significant 
number of boys with DMD also display behaviors on the autistic spectrum (Banihani et al. 
2015). 
 
Prenatal exposure to IL-6 in rats leads to increased levels of IL-6 in the hippocampus which 
are associated with altered expression of NMDA and GABAA receptors and deficits in spatial 
learning (Samuelsson et al. 2006). This has led to the proposal that exposure to pathological 
levels of IL-6 during critical stages of neurodevelopment may contribute to deficits in 
cognitive function. Although it is currently unknown if IL-6 is elevated locally in brain 
regions such as the hippocampus in mdx mice, given that elevated IL-6 levels are a hallmark 
of dystrophin-deficiency and are elevated in mdx plasma (Pelosi et al. 2015), it is possible 
that this may be a factor in dystrophinopathy-associated hippocampal dysfunction.  
 
TNFα 
TNFα concentration is elevated in both DMD patients and in mdx mice, with glial cells 
representing a likely sources of endogenous TNF (Stellwagen and Malenka 2006). 
Interestingly, in an mdx IL-6 mouse, where IL-6 levels are elevated, TNFα levels are also 
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potentiated (Pelosi et al. 2015). Activation of hippocampal TNF 1 receptors increases the 
frequency and amplitude of mEPSCs, which stimulates an increase in the expression of 
AMPA receptors and an overall increase in synaptic strength (Beattie et al. 2002; Dummer et 
al. 2002). Weakening of inhibitory synaptic input also contributes to the excitatory effects of 
TNFα on hippocampal neurons, which may be due to a persistent decrease of inhibitory 
synaptic strength caused by downregulation of membrane expressed GABAA receptors 
(Pribiag and Stellwagen 2013). While not consistent with the changes in electrophysiological 
properties of dystrophin deficient hippocampal neurons, it remains to be elucidated whether 
this inflammatory molecule may have a compensatory role in cognitive dysfunction in 
dystrophinopathies.  
 
Other possible contributory factors in DMD-related cognitive dysfunction 
Nitric oxide (NO) 
In a manner similar to that proposed for elevated levels of peripherally-released cytokines 
altering hippocampal function, others have discovered that peripherally released NO, which 
is decreased in DMD, also exerts neuromodulatory effects. DMD patients and mdx mice 
display up to an 80% reduction of nitric oxide synthase (NOS) activity as loss of dystrophin 
leads to a secondary loss of nNOS from muscle (Brenman et al. 1995; Chang et al. 1996). As 
muscle is the primary source for systemic NO, and this is reduced in DMD patients, Deng 
and colleagues investigated if this impacted upon hippocampal neurogenesis in the mdx 
mouse. Adult neurogenesis within the hippocampus is a proposed means by which alterations 
in synaptic plasticity and memory formation may occur. They found that neurogenesis was 
disrupted in mdx hippocampal tissue (Deng et al. 2009). However, normal neurogenesis was 
restored by increasing muscle, and subsequently serum, NO levels (Deng et al. 2009), 
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evidence that further supports the potential role of peripheral molecules in hippocampal 
dysfunction in dystrophinopathies. 
 
Mitochondrial dysfunction  
Loss of dystrophin in skeletal muscle results in structurally unstable fibres which are more 
porous to the extracellular environment resulting in excessive influx of calcium. Poor calcium 
handling and subsequent activation of proteases and/or lipases leads to calcium overload in 
the cellular mitochondria and subsequent muscle degeneration. As mitochondrial ATP is 
crucial to a myriad of physiological functions, dysregulation of cellular energy homeostasis is 
likely to contribute to dystrophinopathy-associated pathophysiology, including impaired 
intracellular calcium signalling in skeletal muscle and in the brain (Timpani et al. 2015). 
Tracey et al. (1996) found evidence of raised inorganic phosphate ratio, relative to ATP, 
phosphocreatine and phosphomonomers, in DMD brains (Tracey et al. 1995) and there is also 
evidence that the concentration of choline-containing compounds is increased in DMD brains 
(Kato et al. 1997; Rae et al. 1998), which is usually interpreted as being due to increased 
membrane turnover and degradation, or decreased membrane stability, also seen in a number 
of other brain disorders (Anderson et al. 2002). Although in contrast, a more recent study 
showed a deficit in total choline in the brains of DMD patients (Kreis et al. 2011).  
 
The mdx mouse has raised hippocampal choline-containing compounds (Rae et al. 2002; Xu 
et al. 2015), inorganic phosphate, pH and reduced total creatine (Tracey et al. 1996). The fact 
that these metabolic changes are also detected in muscle (Tracey et al. 1996) suggest bio-
energetic similarities in other tissues that lack dystrophin. Uptake of glucose in mdx mice is 
increased relative to controls, reflecting an increase in metabolism, a finding which may 
indicate increased brain activity due to decreased GABA-evoked inhibition (Rae et al. 2002). 
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The fact that the GABA agonist muscimol, had a reduced dampening effect on glucose 
metabolism in mdx brains (Rae et al. 2002) is consistent with this theory in addition to the 
reduction and abnormal clustering of synaptically-located GABAA receptors in the 
hippocampus, cerebellum, amygdala and cerebral cortex (Knuesel et al. 1999; Knuesel et al. 
2001; Kueh et al. 2011; Kueh et al. 2008; Perronnet and Vaillend 2010; Sekiguchi et al. 
2009). A recent study has demonstrated a significant deficit in the amount  of GABA within 
the hippocampal region of mdx mice and raised concentrations of the anti-oxidant molecule 
glutathione (Xu et al. 2015), a likely compensatory development against the increased 
quantity of reactive oxygen species produced by increased metabolism.  
 
Such alterations in cellular metabolism, energy requirements and redox status in mdx brain 
tissue might also be expected to influence neuronal responses to hypoxia in dystrophic brain 
tissue. And indeed, this has proved to the case, with CA1 hippocampal neurons displaying 
particular sensitivity to hypoxic insults, with greater and more rapidly developing decreases 
in synaptic transmission relative to control brain slices at Schaffer collateral – CA1 synapses 
(Godfraind et al. 2000; Mehler et al. 1992). This altered response to hypoxia of mdx mouse 
hippocampal neurons may be due to a combination of factors including reduced GABAA 
receptor clustering in dystrophic neurons, as GABAA receptor activation exacerbates oxygen-
glucose deprivation-induced neuronal injury (Muir et al. 1996). However, Godfraind et al., 
(2000) hypothesised that the more rapid failure of nerve conduction in the dystrophic tissue 
under hypoxic conditions was due to ‘excessive leakiness’ of nerves and poor regulation of 
ionic homeostasis, possibly due to Na-K and/or calcium ATPase activity. Disrupted cellular 
calcium ATPase activity, with a knock on effect on cellular calcium homeostasis, has been 
well described in dystrophic muscle and also seems to be mirrored in certain neural tissues. 
Although studies have not shown that elevated intracellular calcium levels or the number of 
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calcium-positive neurons were actually associated with frank neuronal loss per se in the mdx 
mouse (Tuckett et al 2014), modulation of synaptic plasticity (both LTP and LTD) is a 
calcium-dependent process that is absolutely contingent upon tight spatiotemporal control of 
intracellular neuronal calcium concentration (for review see Baker et al. 2013; Malenka and 
Bear 2004). Therefore, any dysregulation of calcium homeostasis or calcium signalling 
pathways would undoubtedly disrupt both short- and long-term plasticity in affected neurons 
and may at least partially account for some of the cognitive deficits observed in the mdx 
mice.  
 
Matrix Metalloproteinases  
Matrix metalloproteinases (MMPs) are a large family of zinc-dependent extracellular and 
membrane-bound endopeptidases that can cause proteolysis of selected components of the 
extracellular matrix in skeletal muscle. MMP-9 is one member of the family that is expressed 
at low levels under basal conditions but which can be induced by numerous factors, including 
inflammatory cytokines (Hu et al. 2007). MMP-9 is also important in synaptic plasticity, 
thereby contributing to learning and memory. For example, MMP-9 knockout mice exhibited 
deficits in particular components of CA1 LTP and spatial learning (Nagy et al. 2006). 
Furthermore, pharmacological inhibition of MMP-9 resulted in destabilization of LTP 
(Wojtowicz and Mozrzymas 2010). MMP-9 is a key molecule in the regulation of dendritic 
spine morphology and has been implicated in several neurological disorders (Stawarski et al. 
2014). In the context of the dystrophinopathies, MMP-9 is elevated in mdx skeletal muscle 
(Kherif et al. 1999; Li et al. 2009). Thus, MMP-9 represents a possible molecule, possibly 
secondary to raised cytokine levels, which could be an important contributory factor in 
hippocampal dysfunction in DMD patients. 
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Stress  
Immune cells respond not only to tissue damage and infection by secreting cytokines, but 
also to stress, both physical and psychological in nature. Thus, stress may also indirectly 
contribute to inflammatory-related hippocampal dysfunction in DMD patients. However, the 
hippocampus is also directly affected by stress factors and is, in fact, susceptible to damage 
by acute psychological stress, resulting in difficulties in memory retrieval and the acquisition 
and storage of new memories (Sapolsky 1996). In DMD patients the contributory effects of 
chronic corticosteroid exposure on behavior is controversial. Long-term treatment with 
corticosteroids, used in DMD to suppress chronic inflammation, is associated with changes in 
mood, memory and attention (Brown et al. 2008), although not all studies detected such 
changes (Banihani et al. 2015). Nonetheless, DMD patients do exhibit an increased incidence 
of anxiety and depression (Banihani et al. 2015; Fitzpatrick et al. 1986; Pangalila et al. 2015). 
Mdx (Manning et al. 2014) and also mdx3cv (Vaillend and Ungerer 1999) mice, which lack 
Dp427, Dp71 and Dp140 display stress-related behaviors comparable to symptoms of 
depression and anxiety, although not all behavioral assessments detected signs of anxiety in 
dystrophic mice (Sekiguchi et al. 2009). Enhanced freezing behavior in response to restraint 
stress, which is not painful but induces a psychological stress, was also observed in mdx mice 
but it should be noted that this was not associated with any change in corticosteroid levels 
(Yamamoto et al. 2010). Nonetheless, we have observed the efficacy of the tricyclic anti-
depressant, amitriptyline in alleviating depressive and anxiety-like behaviors displayed by 
mdx mice, changes that were linked to altered levels of hippocampal neurotransmitters 
(Manning et al. 2014). It remains to be seen if loss of dystrophin from the CNS contributes 
directly to a heightened stress responses or if these effects are secondary to the disease itself. 
Moreover, further research must be carried out to determine if cross talk between the stress 
axis and the immune system are important in cognitive dysfunction in DMD.  
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Conclusions 
DMD is a devastating disease characterized by a progressive loss of physical function and 
premature death in affected boys. Despite the continuing absence of an effective cure, 
palliative treatments, including prednisone and respiratory ventilation, are extending the life 
expectancy and life quality of patients. As such, investigation into the cognitive deficits and 
co-morbid CNS disorders associated with loss of dystrophin from neurons in the CNS is an 
emerging area of research. Boys with DMD exhibit non-progressing cognitive dysfunction, 
with deficits in verbal, short-term and working memory. In the genetically comparable 
dystrophin-deficient mdx mouse model of DMD, specific deficits in synaptogenesis and 
channel clustering at synapses is evident and deficits in some, but not all, types of learning 
and memory have been identified. Key changes underlying hippocampal dysfunction in 
dystrophin-deficient models are alterations in the number and clustering of post-synaptic 
receptors. The absence of dystrophin results in malformed and dysfunctional synapses which 
are likely to disturb the precise and coordinated neural network activity crucial to the 
formation and consolidation of memories in the hippocampus. Indeed, loss of inhibitory input 
in the mdx hippocampus was associated with abnormally enhanced NMDA-induced Schaffer 
collateral - CA1 LTP, which was sensitive to a GABAA antagonist. It is as yet unclear how 
enhanced LTP in a dystrophin-deficient hippocampus results in deficits in learning and 
memory. However, other studies have revealed that loss of neuronal dystrophin is associated 
with alterations in cellular metabolism, energy requirements and redox status, resulting in 
hippocampal neurons being particularly vulnerable to hypoxic insults, all of which may 
contribute to hippocampal dysfunction. Furthermore, psychological stress can negatively 
impact upon hippocampal function resulting in difficulties in memory retrieval and the 
storage of new memories. We have also identified the potential importance of inflammatory 
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mediators, which are chronically elevated in peripheral tissue and plasma of DMD patients 
and mdx mice, in hippocampal function. Key pro-inflammatory cytokines such as IL-1β, 
TNFα and IL-6 exert neuronmodulatory effects on the hippocampus and have been linked to 
altered capacities for learning and the formation of memories. This novel research avenue 
may reveal the importance of neuroimmune interactions in the CNS of dystrophin-deficient 
patients. Whilst this is a research area still in its infancy, our understanding of both normal 
cognitive function in healthy brains, as well as specific cognitive deficits in the brains of 
those suffering from DMD will be improved by continuing research in this field.  
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